|
|
|
|
Many cancer targets present hurdles in biophysical characterization, especially for PROTACs. Learn how a Spectral Shift affinity screening platform enables precise measurement of complex interactions, accelerating your development of novel degraders.
|
|
|
|
|
Spectral Shift technology enables rapid, resource-conserving biophysical screening for critical drug targets. A study targeting $\text{MEK}1$ successfully identified and validated multiple high-priority binding hits. Learn how this can accelerate your drug discovery efforts.
|
|
|
|
|
Gain highly sensitive, precise binding affinity measurements for membrane proteins without disrupting their native structure. Learn how to stabilize these critical drug targets using detergent-free technology for reliable interaction data.
|
|
|
|
|
Developing PROTACs for undruggable cancer targets requires precise biophysical characterization. Learn how Spectral Shift technology accurately evaluates binary and ternary affinities to provide critical insights into degrader performance.
|
|
|
